NPPA and cardiac hypertrophy: In this line of evidence, our report clearly shows that sorafenib suppressed expression of both the pro-hypertrophic effector ANP and its transcription factor GATA4, and that sorafenib may therefore be an interesting treatment strategy for cardiac hypertrophy.